SORILUX Drug Patent Profile
✉ Email this page to a colleague
When do Sorilux patents expire, and what generic alternatives are available?
Sorilux is a drug marketed by Mayne Pharma and is included in one NDA. There are two patents protecting this drug.
The generic ingredient in SORILUX is calcipotriene. There is one drug master file entry for this compound. Eight suppliers are listed for this compound. Additional details are available on the calcipotriene profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sorilux
A generic version of SORILUX was approved as calcipotriene by FOUGERA PHARMS on May 6th, 2008.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for SORILUX?
- What are the global sales for SORILUX?
- What is Average Wholesale Price for SORILUX?
Summary for SORILUX
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 56 |
| Clinical Trials: | 5 |
| Patent Applications: | 7,053 |
| Drug Prices: | Drug price information for SORILUX |
| What excipients (inactive ingredients) are in SORILUX? | SORILUX excipients list |
| DailyMed Link: | SORILUX at DailyMed |
Recent Clinical Trials for SORILUX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Skin Sciences, PLLC | Phase 4 |
| Tulane University | Early Phase 1 |
| Mayne Pharma International Pty Ltd | Early Phase 1 |
Pharmacology for SORILUX
| Drug Class | Vitamin D Analog |
US Patents and Regulatory Information for SORILUX
SORILUX is protected by five US patents.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | SORILUX | calcipotriene | AEROSOL, FOAM;TOPICAL | 022563-001 | Oct 6, 2010 | RX | Yes | Yes | 8,629,128 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Mayne Pharma | SORILUX | calcipotriene | AEROSOL, FOAM;TOPICAL | 022563-001 | Oct 6, 2010 | RX | Yes | Yes | 8,263,580 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SORILUX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Mayne Pharma | SORILUX | calcipotriene | AEROSOL, FOAM;TOPICAL | 022563-001 | Oct 6, 2010 | 8,269,128 | ⤷ Start Trial |
| Mayne Pharma | SORILUX | calcipotriene | AEROSOL, FOAM;TOPICAL | 022563-001 | Oct 6, 2010 | 8,629,128 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SORILUX
See the table below for patents covering SORILUX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Austria | 381315 | ⤷ Start Trial | |
| Australia | 2006253913 | Vitamin formulation | ⤷ Start Trial |
| Australia | 6069299 | Mousse composition | ⤷ Start Trial |
| Australia | 760153 | ⤷ Start Trial | |
| Brazil | 9913154 | Composição de musse | ⤷ Start Trial |
| Canada | 2333869 | COMPOSITION DE MOUSSE (MOUSSE COMPOSITION) | ⤷ Start Trial |
| Canada | 2611147 | PREPARATION VITAMINEE (VITAMIN FORMULATION) | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch